AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05661162 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CR 500™ SINGLE-DOSE GEL
Description: CR 500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to attenuate the physiological degeneration of cartilage typical of osteoarthritic processes. The presence of sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility
Study NCT06037187 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: Standard coagulation assays (aPTT, INR, ACT), viscoelastic coagulation profiles (rotational thromboelastometry (ROTEM)/thromboelastography (TEG), tPA-challenged ROTEM/TEG), and molecular profiling
Study NCT04538820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg IV-control
Description: dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to normal weight patients.
Study NCT04538820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg IV
Description: dexamethasone 4 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
Study NCT04538820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 8 mg IV
Description: dexamethasone 8 mg will be administered at induction of anesthesia for postoperative nausea and vomiting proflaxis to obese patients
Study NCT05794022 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biocollection
Description: Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.
Study NCT05794022 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of life questionaries
Description: EQ-5D-5L and HAD questionaries at 1 month and 1 year.
Study NCT04841434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voraxaze Injectable Product
Description: High-dose Methotrexat Infusion: MTX is given at a dose according to the allocated dose level cohort as a 4-hour IV infusion. HD-MTX cycles (up to 6) should be repeated every 14 days, provided that the patient has recovered (i.e., hematopoietic reconstitution) between cycles. A delay of up to 28 days between cycles is permitted in order to allow patients to recover from the preceding dose of MTX. In patients with a decline of the GFR to \<40 mL/min, or in the case of decreased GFR, the decrease is >50% compared with the pretreatment value, treatment will be terminated. At the start of Cycle 3 the dose of MTX can be escalated to the next level if MTX has been well-tolerated according to the criteria described under dose escalation. Voraxaze: 2000 Units in patients weighing ≤100kg and at least 20 Units per kg body weight in patients weighing >100kg is given in each HD-MTX cycle as a slow IV injection at 24 hours (+/- 2 hours) after the start of HD-MTX infusion.
Study NCT05360459 — intervention group
Intervention type: RADIATION
Intervention: Exposure to radiotherapy
Description: Characterization and quantification of intestinal and vaginal microbiota in patients affected by cervical or endometrial cancer who have received pelvic radiotherapy more than 24 months ago.
Study NCT06412029 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-interventional study
Study NCT00881413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Intravenous esomeprazole (Nexium®, AstraZeneca, Sodertalje, Sweden) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral esomeprazole 40 mg (Nexium®, AstraZeneca, Sodertalje, Sweden) for 2 months
Study NCT00881413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: After successful endoscopy, intravenous pantoprazole (Pantoloc®, Nycomed GMBH, Konstanz, Germany) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral pantoprazole 40 mg (Pantoloc®, Nycomed GMBH, Oranienburg, Germany) for 2 months
Study NCT04701034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring)
Description: infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
Study NCT04701034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Tablets
Description: 5 mg before ET and 10 mg after ET until gestational week 8+0
Study NCT04701034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human Albumin Solution
Description: Infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
Study NCT04701034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 1 tablet before ET and 2 tablets after ET until gestational week 8+0
Study NCT04977037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Anodal tDCS will be placed over the primary motor cortex and delivered at 2mA for 20 minutes. Immediately after stimulation ceases, participants will continue with unilateral repetitive arm and finger exercises for 60 minutes. Exercise difficulty will gradually be increased and adjusted per participant's tolerance.
Study NCT04977037 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Anodal tDCS will be placed over the primary motor cortex and delivered at 2mA for 20 minutes. Immediately after stimulation ceases, participants will continue with unilateral repetitive arm and finger exercises for 60 minutes. Exercise difficulty will gradually be increased and adjusted per participant's tolerance.
Study NCT05088031 — intervention group
Intervention type: DEVICE
Intervention: shock waves therapy
Description: Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head 2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest)
Study NCT04615845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellgram-DC-PC
Description: Patients will receive 3 times every 2 weeks injection of Cellgram-DC-PC(Autologous dendritic cell) subcutaneously near the inguinal lymph nodes
Study NCT05002114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Topical CBD cream - special formulation
Study NCT05002114 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Not the drug
Study NCT05132569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolebrutininb
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral
Study NCT05132569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutininb
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral
Study NCT05132569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral
Study NCT05270928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI346
Description: IBI346 Antibody and IBI346 CAR-T cell injection
Study NCT06242067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Description: patients received biweekly Trifluridine/tipiracil (30 mg/m2 twice daily; days 1-5), irinotecan (150 mg/m2; day 1) and bevacizumab (5 mg/kg; day 1).
Study NCT06217016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICCAUT
Description: In this study ,the ICCAUT strategy include intermittent catheter clamping and active urination training. For patients in the ICCAUT group, intermittent catheter clamping will be initiated at 9:00 AM. The catheter will be clamped for 3 h, followed by a 5-minute release, which is one cycle. The next cycle will begin after the cycle was completed. Catheter training is to conclude at 10:00 PM on the first postoperative day, and the catheter is left open during the night. At 6:00 AM on the second postoperative day, another cycle of catheter training will be performed, with the catheter removed at 9:00 AM. During the training period, if the patient experiences a strong urge to urinate before the 3-hour clamping time is over, the clamping can be released in advance for 5 min, allowing the patient to proceed to the next cycle of bladder training. Each time the catheter is released, we will encourage the patients to actively initiate urination to facilitate complete bladder emptying.
Study NCT06217016 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Free drainage
Description: For patients in the free draining group, no intervention will be performed on the catheter during this period. The catheter will be removed at 9:00 AM on postoperative day two.
Study NCT05918822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Commercial Tablet Formulation
Description: Maribavir commercial tablet.
Study NCT05918822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Pediatric Powder-for-oral Suspension Formulation
Description: Maribavir pediatric powder-for-oral suspension.
Study NCT05525767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: All subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
Study NCT05918822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole tablet.
Study NCT05562466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QMF149
Description: QMF149 75/40 μg o.d via Breezhaler
Study NCT05562466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Budesonide 200 μg o.d via Breezhaler
Study NCT06077019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol and Fluticasone Furoate
Description: Participants inhale 25 µg vilanterol + fluticasone furoate daily
Study NCT06077019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol and Mometasone Furoate
Description: Participants inhale 125 µg indacaterol + mometasone furoate daily
Study NCT06077019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants inhale placebo daily
Study NCT04665661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training
Description: Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).
Study NCT04665661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity aerobic training
Description: Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).
Study NCT04665661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wait-list control
Description: Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
Study NCT04665661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list control
Description: Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
Study NCT06295419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual task
Description: cerebral palsy and healthy controls will be evaluated dual task conditions
Study NCT06295419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single task
Description: cerebral palsy and healthy controls will be evaluated single task conditions
Study NCT05655637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: There will be one group, and study will be Quasi Experimental Study. Treatment will be given to all 28 participants, 3 sessions in a week for 4 weeks. Pre and Post treat-meant evaluation will be checked by CFQR+14. All patients will be treated with exercise program of Active cycle breathing techniques(ACBT), Pursed lip breathing, Endurance Exercise 20 to 30 min ( walking, cycling) and strength training with Thera-Bands (Bilateral arm raising, Bilateral knee extension). Exercise capacity will be measured with 6MWT. Dyspnea and fatigue will be measured with Borg scale.
Study NCT06354270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Description: Toothpaste containing 0.454 % weight/weight (w/w) SnF2.
Study NCT06354270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular fluoride toothpaste (Crest Cavity Protection)
Description: Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
Study NCT04761094 — intervention group
Intervention type: DEVICE
Intervention: Insulin pump
Description: Treatment with continuous subcutaneous insulin infusion
Study NCT04371536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: Patients receive ferrous sulfate 3 mg/kg elemental iron once daily in liquid formulation.
Study NCT04371536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: Patients receive ferrous sulfate 3 mg/kg elemental iron once daily in liquid formulation.
Study NCT05370261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine LipoMicel
Description: Berberine LipoMicel® soft-gels. Total dose of 500 mg of berberine
Study NCT05370261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Regular Berberine hard-gels
Description: Total dose of 500 mg of berberine
Study NCT05449782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cocoa flavanol
Description: Commercially available Cocoa Via Brand capsules containing 1350 mg cocoa flavanols (6 capsules)
Study NCT05449782 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Capsules identical to ccocoa flavanol capsules filled with calorically matched brown sugar (6 capsules)
Study NCT06248086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2802
Description: Intravenous (IV) infusion
Study NCT06248086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MA-20
Description: IV infusion
Study NCT04715685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 40 minute session
Description: The 40 minute session will include all of the content contained in the 20 minute session, but will include a greater explanation of each of the mind and body skills, followed by in vivo practice of each skill with the nurse. Sessions will also include review of home practice for each group.
Study NCT04715685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 20 minute session
Description: For participants randomized to the 20 minute session, content will include pain education, followed by brief explanations of each of the mind and body skills, in vivo diaphragmatic breathing practice and demonstration of use of biofeedback card. Sessions will also include review of home practice for each group.
Study NCT04715685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home practice e-health
Description: Participants will be provided and instructed on access to a migraine-specific interactive web portal, Migraine e-Health. This web-based tool actively guides participants in practicing evidence-based mind and body skills. Use of the Migraine -e-Health application for the high dose capitalizes on teaching participants mind and body skills while increasing accessibility due to implementation on mobile devices.
Study NCT04715685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home practice handout
Description: Participants will be given a handout of commercially available free apps relevant to the mind body skills introduced.
Study NCT04715685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phone call
Description: The dose of phone call will occur about 4 weeks following the face-to-face mind and body introduction session and will last approximately 5-10 minutes. The phone call will be used to promote adherence to home-practice and answer questions related to skill use/home practice completion.
Study NCT04371536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IRONCHILD
Description: Delivery of the intervention at each visit should take 15 minutes or less.~* Baseline visit (Session 1) content will be viewed~* At 1-month follow-up visit, additional (Session 2) content will be viewed~* At 3-month final visit, patients will view final (Session 3) content
Study NCT06630806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR446523
Description: Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)
Study NCT05417542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEG
Description: EEG recording during prematurity or around term
Study NCT05417542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG recording during prematurity or around term
Study NCT05417542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIRS
Description: NIRS recording during prematurity or around term
Study NCT05417542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIRS
Description: NIRS recording during prematurity or around term
Study NCT05150613 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Mask
Description: Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
Study NCT06186609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor 200mg per three to four weeks, for one year
Description: PD-1 inhibitor delivered 200mg once before radiotherapy and 200mg every 3-4 weeks after radiotherapy for one year.~Radiotherapy:56-60Gy/28-30 fraction.
Study NCT05150613 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surgical Mask
Description: Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
Study NCT05752292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Health Information
Description: Standard health information about postpartum screening and lifestyle programs for diabetes prevention
Study NCT05752292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values Affirmation (VA)
Description: Interactive prompts to reflect on core personal values
Study NCT05752292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Risk Information (TRI)
Description: Interactive prompts to provide tailored information on risk factors for type 2 diabetes